Design of Organic Macrocycle-Modified Iron Oxide Nanoparticles for Drug Delivery

5 years ago

Design of Organic Macrocycle-Modified Iron Oxide Nanoparticles for Drug Delivery

Ali Trabolsi, Farah Benyettou, Tina Skorjanc, John-Carl Olsen

Paul Ehrlich's vision of a “magic bullet” cure for disease inspires the modern design of nanocarriers whose purpose is to deliver drug cargo to specific sites in the body while circumventing endogenous immunological clearance mechanisms. Iron oxide nanoparticles (IONPs) have emerged as particularly promising nanocarriers because of their biodegradability, ability to be guided magnetically to sites of pathology, mediation of hyperthermic therapy, and imaging capabilities. In this review, we focus on the design and drug-delivery aspects of IONPs coated with organic macrocycles (crown ethers, cyclodextrins, calix[n]arenes, cucurbit[n]urils, or pillar[n]arenes), which, by means of reversible complexation, allow for the convenient loading and release of drug molecules. Macrocycles can be attached to IONPs indirectly or directly. Indirect attachment requires the use of small organic linking molecules or conjugation to shell materials. Direct attachment requires neither. We discuss in detail drug release from the macrocycles, highlighting mechanisms that depend on external stimuli such as changes in pH, the competitive binding of ions or small molecules, or the application of ultrasound or electromagnetic radiation. Wrapping up nanoparticles: Current strategies for synthesizing macrocycle-modified iron oxide nanoparticles for drug delivery are described, and the corresponding mechanisms of controlled drug release are discussed (see figure).

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1002/chem.201605246